Clinical Trial: A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa

U.S., Sept. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07174726) titled 'A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa' on Sept. 05.

Brief Summary: The purpose of this Phase 2 Study is to see if the investigational study drug, laruparetigene zovaparvovec, also known as AGTC-501, given in both eyes, is safe and works to preserve and/or improve vision and other symptoms of XLRP.

Study Start Date: Sept. 10

Study Type: INTERVENTIONAL

Condition: X-Linked Retinitis Pigmentosa (XLRP)

Intervention: BIOLOGICAL: Adeno-associated virus vector expressing a human RPGR gene

Male participants 12-5...